FindTrial
Sign In

Clinical study on mitochondrial genome mutation in monitoring postoperative recurrence of urothelial carcinoma

Clinical study on mitochondrial genome mutation in monitoring postoperative recurrence of urothelial carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500100248
Enrollment
Unknown
Registered
2025-04-07
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial carcinoma

Interventions

Gold Standard:Pathological biopsy
Index test:Mitochondrial DNA testing

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age: 18 years old and above; 2. Patients clinically diagnosed with urothelial carcinoma requiring surgery; 3. Clinical staging T1-2N0M0; 4. Postoperative imaging shows no evidence of residual disease; 5. Patient signs informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with other active tumors or severe complications; 2. The patient's tumor has undergone distant metastasis; 3. Insufficient tumor tissue for MRD detection; 4. Patients undergoing total cystectomy.

Design outcomes

Primary

MeasureTime frame
Number of mitochondrial DNA mutations;—

Secondary

MeasureTime frame
Abundance of mitochondrial DNA mutations;—

Countries

China

Contacts

Public ContactHan Bangmin, Lou Jiatao

Shanghai General Hospital

hanbm@163.com+86 189 3975 7031

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026